IMGN insider transaction filings

ImmunoGen, Inc. — 39 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-02-12. Screen IMGN transaction legs live →

Insider transaction summary — last 90 days

No Form 4 filings for IMGN between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.

Recent Form 4 filings — ImmunoGen, Inc.

FiledFormInsiderReported transactionsSource
2024-02-124Kalofonos Isabel — SVP & CHIEF COMMERCIAL OFFICERDisposition to issuer (D): 284,250 (derivative) · Disposition to issuer (D): 47,375 (derivative) · Disposition to issuer (D): 19,458 (derivative)EDGAR
2024-02-124White Lauren — SVP, CFO AND PFODisposition to issuer (D): 295,975 (derivative) · Disposition to issuer (D): 51,625 (derivative) · Disposition to issuer (D): 19,519 (derivative)EDGAR
2024-02-124Lentini Renee — VP & PRIN ACCTG OFFICERDisposition to issuer (D): 14,723 · Disposition to issuer (D): 39,370 (derivative) · Disposition to issuer (D): 8,250 (derivative) · Disposition to issuer (D): 6,555 (derivative) · Disposition to issuer (D): 12,625 (derivative) · Disposition to issuer (D): 25,250 (derivative) · +3 moreEDGAR
2024-02-124Coen Stacy Ann — SVP & CHIEF BUSINESS OFFICERDisposition to issuer (D): 73,274 · Disposition to issuer (D): 150,610 (derivative) · Disposition to issuer (D): 303,465 (derivative) · Disposition to issuer (D): 258,195 (derivative) · Disposition to issuer (D): 65,000 (derivative) · Disposition to issuer (D): 28,700 (derivative) · +1 moreEDGAR
2024-02-124Char Daniel — SVP & CHIEF LEGAL OFFICERDisposition to issuer (D): 1,000 · Disposition to issuer (D): 400,000 (derivative) · Disposition to issuer (D): 22,825 (derivative)EDGAR
2024-02-124VASCONCELLES MICHAEL — EVP R&D & MEDICAL AFFAIRSDisposition to issuer (D): 1,327 · Disposition to issuer (D): 960,000 (derivative) · Disposition to issuer (D): 50,515 (derivative)EDGAR
2024-02-124McCain Tracey L — DirectorDisposition to issuer (D): 13,090 (derivative) · Disposition to issuer (D): 50,303 (derivative) · Disposition to issuer (D): 19,597 (derivative) · Disposition to issuer (D): 25,556 (derivative) · Disposition to issuer (D): 44,000 (derivative)EDGAR
2024-02-124Thackray Helen M. — DirectorDisposition to issuer (D): 3,074 · Disposition to issuer (D): 13,090 (derivative) · Disposition to issuer (D): 40,932 (derivative) · Disposition to issuer (D): 44,000 (derivative) · Disposition to issuer (D): 32,066 (derivative) · Disposition to issuer (D): 19,597 (derivative)EDGAR
2024-02-124Enyedy Mark J — CHIEF EXECUTIVE OFFICER, DirectorDisposition to issuer (D): 584,397 · Disposition to issuer (D): 102,466 (derivative) · Disposition to issuer (D): 140,357 (derivative) · Disposition to issuer (D): 196,875 (derivative) · Disposition to issuer (D): 925,000 (derivative) · Disposition to issuer (D): 1,100,000 (derivative) · +2 moreEDGAR
2024-02-124Arbuckle Stuart A — DirectorDisposition to issuer (D): 5,381 · Disposition to issuer (D): 13,090 (derivative) · Disposition to issuer (D): 63,000 (derivative) · Disposition to issuer (D): 4,167 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 15,800 (derivative) · +5 moreEDGAR
2024-02-124Goldberg Mark Alan — DirectorDisposition to issuer (D): 60,720 · Disposition to issuer (D): 13,090 (derivative) · Disposition to issuer (D): 160,350 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 5,000 (derivative) · +7 moreEDGAR
2024-02-124Wingrove Theresa — SVP OF REGULATORY AFFAIRSDisposition to issuer (D): 21,039 · Disposition to issuer (D): 35,871 (derivative) · Disposition to issuer (D): 121,905 (derivative) · Disposition to issuer (D): 115,273 (derivative) · Disposition to issuer (D): 140,400 (derivative) · Disposition to issuer (D): 87,500 (derivative) · +7 moreEDGAR
2024-02-124Peterson Kristine — DirectorDisposition to issuer (D): 13,090 (derivative) · Disposition to issuer (D): 74,954 (derivative) · Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · +4 moreEDGAR
2024-02-124Wallace Richard John — DirectorDisposition to issuer (D): 10,000 · Disposition to issuer (D): 13,090 (derivative) · Disposition to issuer (D): 102,326 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 5,000 (derivative) · +7 moreEDGAR
2024-02-124MITCHELL DEAN J — DirectorDisposition to issuer (D): 103,000 · Disposition to issuer (D): 13,090 (derivative) · Disposition to issuer (D): 142,667 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · +3 moreEDGAR
2024-02-124MCCLUSKI STEPHEN C — DirectorDisposition to issuer (D): 13,090 (derivative) · Disposition to issuer (D): 105,458 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · +6 moreEDGAR
2024-02-064Lentini Renee — VP & PRIN ACCTG OFFICEROption exercise (M): 8,435 @ $0 · Sale (S): 2,631 @ $29.30 · Option exercise (M): 8,435 (derivative) @ $0EDGAR
2024-02-064Coen Stacy Ann — SVP & CHIEF BUSINESS OFFICEROption exercise (M): 14,350 @ $0 · Sale (S): 4,583 @ $29.30 · Option exercise (M): 14,350 (derivative) @ $0EDGAR
2024-02-064Enyedy Mark J — CHIEF EXECUTIVE OFFICER, DirectorOption exercise (M): 51,234 @ $0 · Sale (S): 20,107 @ $29.28 · Option exercise (M): 51,234 (derivative) @ $0EDGAR
2024-02-064Wingrove Theresa — SVP OF REGULATORY AFFAIRSOption exercise (M): 29,640 @ $0 · Sale (S): 12,027 @ $29.30 · Option exercise (M): 21,840 (derivative) @ $0 · Option exercise (M): 7,800 (derivative) @ $0EDGAR
2024-02-054Kalofonos Isabel — SVP & CHIEF COMMERCIAL OFFICERGrant/award (A): 19,458 (derivative) @ $0EDGAR
2024-02-054White Lauren — SVP, CFO AND PFOGrant/award (A): 19,519 (derivative) @ $0EDGAR
2024-02-054Lentini Renee — VP & PRIN ACCTG OFFICERGrant/award (A): 10,139 (derivative) @ $0EDGAR
2024-02-054Coen Stacy Ann — SVP & CHIEF BUSINESS OFFICERGrant/award (A): 39,293 (derivative) @ $0EDGAR
2024-02-054Char Daniel — SVP & CHIEF LEGAL OFFICERGrant/award (A): 22,825 (derivative) @ $0EDGAR
2024-02-054VASCONCELLES MICHAEL — EVP R&D & MEDICAL AFFAIRSGrant/award (A): 50,515 (derivative) @ $0EDGAR
2024-02-054Enyedy Mark J — CHIEF EXECUTIVE OFFICER, DirectorGrant/award (A): 140,357 (derivative) @ $0EDGAR
2024-02-054Wingrove Theresa — SVP OF REGULATORY AFFAIRSGrant/award (A): 21,364 (derivative) @ $0EDGAR
2024-01-184Wingrove Theresa — SVP OF REGULATORY AFFAIRSOption exercise (M): 58,900 @ $4.83 · Option exercise (M): 2,667 @ $5.75 · Option exercise (M): 126,100 @ $5.25 · Sale (S): 187,667 @ $29.64 · Option exercise (M): 58,900 (derivative) @ $0 · Option exercise (M): 2,667 (derivative) @ $0 · +1 moreEDGAR
2024-01-034Lentini Renee — VP & PRIN ACCTG OFFICERGrant/award (A): 467 @ $16.01EDGAR
2024-01-034Coen Stacy Ann — SVP & CHIEF BUSINESS OFFICEROption exercise (M): 30,000 @ $5.32 · Grant/award (A): 367 @ $16.01 · Option exercise (M): 30,000 (derivative) @ $0EDGAR
2024-01-034VASCONCELLES MICHAEL — EVP R&D & MEDICAL AFFAIRSGrant/award (A): 1,327 @ $16.01EDGAR
2024-01-034Thackray Helen M. — DirectorGrant/award (A): 252 @ $29.65EDGAR
2024-01-034Arbuckle Stuart A — DirectorGrant/award (A): 442 @ $29.65EDGAR
2024-01-034Goldberg Mark Alan — DirectorGrant/award (A): 569 @ $29.65EDGAR
2024-01-034Wingrove Theresa — SVP OF REGULATORY AFFAIRSGrant/award (A): 615 @ $16.01EDGAR
2023-12-274Lentini Renee — VP & PRIN ACCTG OFFICEROption exercise (M): 15,000 @ $0 · Sale (S): 6,548 @ $29.74 · Option exercise (M): 15,000 (derivative) @ $0EDGAR
2023-12-194Wingrove Theresa — SVP OF REGULATORY AFFAIRSOption exercise (M): 27,788 @ $4.55 · Option exercise (M): 89,657 @ $5.32 · Sale (S): 117,445 @ $29.40 · Option exercise (M): 27,788 (derivative) @ $0 · Option exercise (M): 89,657 (derivative) @ $0EDGAR
2023-12-194/AMITCHELL DEAN J — DirectorOption exercise (M): 10,000 @ $14.70EDGAR

Recent 8-K events — ImmunoGen, Inc.

FiledFormItems reportedSource
2024-02-128-K1.02 — Termination of a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2024-02-088-K8.01 — Other EventsEDGAR
2024-01-318-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2024-01-298-K8.01 — Other EventsEDGAR
2024-01-248-K8.01 — Other EventsEDGAR
2024-01-088-K8.01 — Other EventsEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=IMGN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →